At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
06185 CANSINOBIO
Not Yet Opened 06-10 16:09:07
23.140
+0.180
+0.78%
High23.160Low22.200Vol541.80K
Open22.940D1 Closing22.960Amplitude4.18%
Mkt Cap5.72BTradable Cap3.07BTotal Shares247.04M
T/O12.27MT/O Rate0.41%Tradable Shares132.67M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.
CanSino Biologics Defines Governance, Capital Structure and Dividend Policy in Updated Articles of Association
Bulletin Express  ·  06-10 20:45
CanSino Biologics Defines Governance, Capital Structure and Dividend Policy in Updated Articles of Association
CANSINOBIO Keeps Share Capital Steady in May; 2.91 Million Shares Reserved for Incentive Plans
Bulletin Express  ·  06-02
CANSINOBIO Keeps Share Capital Steady in May; 2.91 Million Shares Reserved for Incentive Plans
CanSino Biologics Begins Trials of Broad Pneumococcal Conjugate Vaccine
MT Newswires Live  ·  05-26
CanSino Biologics Begins Trials of Broad Pneumococcal Conjugate Vaccine
CANSINOBIO (06185) Initiates Phase I/II Clinical Trial for PCV24 with First Participant Enrolled
Stock News  ·  05-26
CANSINOBIO (06185) Initiates Phase I/II Clinical Trial for PCV24 with First Participant Enrolled
CANSINOBIO Initiates Phase I/II Trial of 24-Valent Pneumococcal Conjugate Vaccine PCV24, Enrolls First Patient
Bulletin Express  ·  05-26
CANSINOBIO Initiates Phase I/II Trial of 24-Valent Pneumococcal Conjugate Vaccine PCV24, Enrolls First Patient
CANSINOBIO Sets 2025 AGM for 10 June 2026; Seeks Share-Issuance, Repurchase and Dividend Mandates
Bulletin Express  ·  05-19
CANSINOBIO Sets 2025 AGM for 10 June 2026; Seeks Share-Issuance, Repurchase and Dividend Mandates
CANSINOBIO Calls 10 June 2026 AGM to Approve 2025 Results, No Dividend Payout, and Fresh Financing Mandates
Bulletin Express  ·  05-19
CANSINOBIO Calls 10 June 2026 AGM to Approve 2025 Results, No Dividend Payout, and Fresh Financing Mandates
CanSino Biologics' Drug Application for Combined Vaccines Granted Priority Review in China
MT Newswires Live  ·  05-11
CanSino Biologics' Drug Application for Combined Vaccines Granted Priority Review in China
CansinoBIO's Td5cp Vaccine for Adolescents and Adults Granted Priority Review by China's Drug Regulator
Stock News  ·  05-11
CansinoBIO's Td5cp Vaccine for Adolescents and Adults Granted Priority Review by China's Drug Regulator
CanSino Biologics Q1 Loss After Two Profitable Quarters Tests Bullish Profitability Narratives
Simply Wall St.  ·  04-30
CanSino Biologics Q1 Loss After Two Profitable Quarters Tests Bullish Profitability Narratives
UBS Lowers CANSINOBIO (06185) Target Price to HK$52.4, Q1 Results In Line
Stock News  ·  04-30
UBS Lowers CANSINOBIO (06185) Target Price to HK$52.4, Q1 Results In Line
CanSinoBIO Proposes Comprehensive Amendments to Articles and Board Procedures to Strengthen Governance
Bulletin Express  ·  04-28
CanSinoBIO Proposes Comprehensive Amendments to Articles and Board Procedures to Strengthen Governance
CANSINOBIO Reports Widened Net Loss in Q1
Stock News  ·  04-28
CANSINOBIO Reports Widened Net Loss in Q1
康希诺生物2025年业绩扭亏为盈，核心疫苗销售推动营收突破10.59亿元
Bulletin Express  ·  04-22
康希诺生物2025年业绩扭亏为盈，核心疫苗销售推动营收突破10.59亿元
CANSINOBIO 2025 ESG Report: GHG Intensity Cut 17.39%, RMB 371 Million R&D Outlay and Multiple Vaccine Milestones
Bulletin Express  ·  04-22
CANSINOBIO 2025 ESG Report: GHG Intensity Cut 17.39%, RMB 371 Million R&D Outlay and Multiple Vaccine Milestones
CanSinoBIO reiterates switch to electronic corporate communications, requests shareholders’ email registration
Bulletin Express  ·  04-22
CanSinoBIO reiterates switch to electronic corporate communications, requests shareholders’ email registration
CANSINOBIO Schedules 28 April Board Meeting to Approve Q1 2026 Results
Bulletin Express  ·  04-16
CANSINOBIO Schedules 28 April Board Meeting to Approve Q1 2026 Results
CanSino Biologics Infant Combination Vaccine Approved in China
MT Newswires Live  ·  04-13
CanSino Biologics Infant Combination Vaccine Approved in China
Hong Kong Grants First Stablecoin Issuer Licenses as Iran-US Talks Show Major Rifts
Stock News  ·  04-13
Hong Kong Grants First Stablecoin Issuer Licenses as Iran-US Talks Show Major Rifts
CANSINOBIO receives NMPA approval for China’s first component-based DTcP vaccine for infants
Bulletin Express  ·  04-12
CANSINOBIO receives NMPA approval for China’s first component-based DTcP vaccine for infants

Introduction

Company Name.
CANSINOBIO
Affiliated Markets:
SEHK
Listing Date:
--
Main Business:
CanSino Biologics Inc is a clinical-stage vaccine company in China. The Company's products include Ad5-EBOV vaccine used for Ebola virus, MCV2 and MCV4 vaccines for meningococcus, PBPV vaccine used for pneumococcal and the recombinant novel coronavirus vaccine. Its products are mainly used in meningitis, diphtheria pertussis tetanus (DPT) and pneumonia.
Issue price:
--